EGFR and breast carcinoma: The gradually evolving models have also been tailored to cancer biology, e.g. in non-small cell lung (NSCLC) and breast cancer, where alterations that can be targeted with systemic anti-cancer drugs (epidermal growth factor receptor (EGFR) mutations etc.)influence assignment to one of three or four prognostic strata, depending on the score used in clinical practice.